Comparing Efficacy of Different Drugs Combinations for Serratus Anterior Block for Thoracotomy

December 9, 2022 updated by: Ahmed Hussein Sayed Hasan, Cairo University

Efficacy of Serratus Anterior Plane Block Using Bupivacaine Alone, Bupivacaine/ Magnesium Sulfate Versus Bupivacaine/ Nalbuphine for Thoracotomy: A Randomized, Double-Blinded Comparative Study.

We aim to compare efficacy and efficiency of serratus anterior block with bupivacaine alone to bupivacaine/magnesium and bupivacaine /nalbuphine in postoperative analgesia for thoracotomy surgery.

Objectives:

To compare bupivacaine alone, bupivacaine/magnesium and bupivacaine /nalbuphine in serratus anterior plane block for intraoperative and postoperative analgesia for thoracotomy surgery.

  • The time for 1st rescue analgesia.
  • Calculation of the opioid requirements; (the total intra-operative post-operative morphine consumption in first 24h postoperative).
  • Assessment of pain score (VAS)- rest, VAS-movement, VAS-cough during post-operative 24hrs period.

Hypothesis:

We hypothesize that magnesium sulfate and nalbuphine can reduce acute postoperative pain and result in efficacious postoperative analgesia due to block of the lateral cutaneous branches of the intercostal nerves (T2 - T6) by diffusion across the inter-fascial planes.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

I. Study design prospective, randomized controlled study. II. Study setting and location It will be conducted at El Kasr Al-Aini hospitals, cardiothoracic Surgery, Cairo University.after registration in clinicaltrials.gov and getting a unique number III. Study population patients of both genders, aged (16 - 65) years old, ASA I, II or III scheduled for elective general thoracotomy surgeries will be included. Consenting patients will be randomly allocated to one of three groups: Group B: patients will receive intraoperative serratus block with bupivacaine. Group BMG: patients will receive intraoperative serratus block with bupivacaine/ magnesium.

Group BN: patients will receive intraoperative serratus block with bupivacaine /nalbuphine.

V. Study Procedures

  1. Randomization:

    The patients will be randomized using a computer-generated list of random numbers which will be sealed in closed envelopes. Patients will be randomly allocated to one of the three groups. The study drugs are going to be prepared by anesthetist (who were blinded to the study and did not share in the technique) in labelled syringes, patients into 3 groups by a sealed opaque envelope, and received the study drug as follows: group B (n = 26): (bupivacaine): received bupivacaine 30 mL 0.25%, group BMG (n =26): received bupivacaine 30 mL 0.25% and 500 mg magnesium sulphate. Group BN (n =26): (bupivacaine/nalbuphine): received bupivacaine 30 mL 0.25 % and nalbuphine 0.2 mg/kg.

  2. Study Protocol All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications.

Laboratory work needed will be: Complete blood count (CBC); prothrombin time and concentration (PT& PC, INR), renal functions and liver function tests or other necessary investigation for the desired surgery. ECG, CXR, CT chest and echocardiography will be done if needed preoperatively Anesthetic application

  • Standard monitoring procedures will include continuous ECG, pulse oximetry, invasive arterial blood pressure, end-tidal CO2, inhaled gas analyzer and temperature monitoring. Baseline readings (T0) of heart rate, systolic, diastolic, and mean blood pressure are going to be record after monitor attachment and every 30 min
  • General anesthesia will be induced in all groups (B, BN, AND BMG group) using fentanyl 2 mic/kg, propofol 2 mg/kg and atracurium 0.5 mg/kg while in obese patients Lean body weight (LBW) will be used. single or double lumen tube will be used as preferred by surgeon, Anesthesia will be maintained using isoflurane (1 MAC) and atracurium supplements were given to maintain muscle relaxation., diclofenac 75mg once iv infusion and acetaminophen 15 mg/kg. Additional dose of fentanyl 1mic / kg will be given if there is tachycardia >100 or intraoperative hypertension more than 20% of the preoperative value. In addition to, all patients will receive cefotaxime 50 mg/kg.

Near the end of surgery, the surgeon is going to aspirate the content of the labelled syringes with a sterile one and ask to inject it below the serratus anterior muscle after closing it. To prevent inadvertent intravascular insertion of the needle, the study drugs are going to be injected in increments after repeated aspiration. At the end of the surgery, inhaled anesthetic is going to discontinue. After the reversal of muscle relaxation and full recovery, patients will be monitored at the recovery unit. Postoperative pain Visual Analogues Scales (VAS, VAS movement, VAS cough) are going to be measure pain (static, dynamic and with cough respectively), where 0 = "no pain" and 10 = "worst pain imaginable", at 1, 6, 12, 24 h by a person not oriented by protocol. Classic postoperative analgesic regimen (Diclofenac 75mg every 8hrs and acetaminophen 1gm every 6 hrs.). The efficacy of the block will be test by measuring the distribution of lost cold sensation along distribution of lateral cutaneous nerve from second intercostal to ninth intercostal nerve.

Morphine 2 mg Iv incremental boluses will be given as rescue analgesia for patients if VAS score >3.

1. Measurement tools

  • Demographic data (age, sex, BW) patient surgery characteristic (duration of the surgery, type of operation) and ASA status will be recorded.
  • In the PACU and the ward, patient will be assessed for the first 24 hours post-operative period using (VAS score) for Pain assessment.

Blood pressure (SBP, DBP and MAP) and heart rate will also be recorded during the operation and the first 24 hours post-operative period and intraoperative fentanyl doses.

Statistical Analysis I. Sample size The time of 1st use of rescue analgesia post-operatively is defined as the primary outcome of the study using one-way ANOVA test. As based on previous study (Comparison of ultrasound-guided serratus plane block and thoracic paravertebral block for postoperative analgesia after thoracotomy, a randomized controlled trial Research and Opinion in Anesthesia & Intensive Care 2018, 5:314-322), the mean time to 1st use of morphine was (6.2 ± 1.66) hours.

If combining the bupivacaine with nalbuphine or with magnesium would result in a 30% increase in the time to 1st use of morphine: α error of 0.05 and power of 0.95. A minimum of 78 patients was calculated (27 patients in each group). sample size was calculated using G-Power version 3.1.9.2 software.

II. Statistical analysis

Analysis of data will be performed using Statistical package for social science (SPSS) software, version 15 for Microsoft Windows (SPSS Inc., Chicago, IL, and USA). Categorical data will be reported as numbers and percentages and will be analyzed using chi-squared test. Continuous data will be checked for normality using Kolmogorov-Smirnov test. Normally distributed data will be presented as means (standard deviations) and will be analyzed using unpaired student t-test. Skewed data will be expressed as medians (quartiles) and will be analyzed using Mann Whitney U test. For repeated measures, a two-way repeated measure ANOVA will be used to evaluate the block (between-groups factor) and the time (repeated measures)". Post-hoc pairwise comparison will be performed using Bonferroni test. P value of 0.05 or less will be considered significant.

Study Type

Interventional

Enrollment (Anticipated)

78

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 65 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Elective thoracotomy or unplanned thoracotomy after failed thoracoscopic surgery
  • Patient with American Society of Anesthesiology ASA I, II or III.

Exclusion Criteria:

  1. Patient refusal

  2. Contraindication for regional anesthesia

    • Allergy from local anesthetics
    • Bleeding diathesis (Bleeding tendency with prothrombin concentration PC less than 75 % or platelet count less than 50,000/µL.
    • Use of anticoagulants, infection at the puncture site.
  3. Presence of severe Chronic renal impairment or acute renal failure, decompensated liver disease, cardiac or psychiatric disorders, GIT ulcers, communication barriers, hearing deficit or high grades of visual deficit that interfere with consenting, VAS assessments, and delirium, or another cognitive dysfunction.
  4. Patient intubated preoperatively.
  5. Patient will not be extubated immediately postoperatively
  6. Opioid tolerant patients.
  7. Any contraindications of Magnesium infusion as hypovolemia or severe impaired ventricular systolic function.
  8. Contraindication of acetaminophen and Diclofenac sodium administration.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group B
bupivacaine
Drug: patients will receive intraoperative serratus block with bupivacaine
no additives
Active Comparator: Group BMG
bupivacaine/ magnesium.
Drug: serratus block with bupivacaine /magnesium
magnesium added
Active Comparator: Group BN
bupivacaine /nalbuphine.
Drug: serratus block with bupivacaine with nalbuphine
nalbuphine added

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The time of 1st rescue analgesia post operative
Time Frame: one year
if VAS or VAS-movement >3.
one year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain assessment score; (VAS score) VAS-movement and VAS-cough
Time Frame: one year
at 1, 6, 12, 24 hours post-operative period
one year
Total amount of morphine (mg) used in 24h post operatively
Time Frame: one year
when VAS >3
one year
Hemodynamic changes (SBP, DB, MAP)
Time Frame: one year
during the first 24 hours in the postoperative period
one year
Incidence of local anesthetic toxicity.
Time Frame: one year
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Study Chair: Tamer M. Atteya, M.D, Lecturer of anesthesia,surgical ICU and pain managment

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 9, 2022

Primary Completion (Anticipated)

September 10, 2023

Study Completion (Anticipated)

November 10, 2023

Study Registration Dates

First Submitted

September 30, 2022

First Submitted That Met QC Criteria

September 30, 2022

First Posted (Actual)

October 4, 2022

Study Record Updates

Last Update Posted (Actual)

December 13, 2022

Last Update Submitted That Met QC Criteria

December 9, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • N-50-2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Operative Pain, Acute

Clinical Trials on patients will receive intraoperative serratus block with bupivacaine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe